An FDA advisory committee voted narrowly to add four peptides to the 503A Bulks List, allowing compounding pharmacies broader use. The decision aligns with HHS Secretary Robert F. Kennedy Jr.'s MAHA agenda but faces concerns over lack of evidence. The panel will debate three more peptides on Friday.
On July 23, 2026, an advisory committee to the Food and Drug Administration voted in closely contested decisions to recommend adding four peptides to the "503A Bulks List." This list permits specialized compounding pharmacies to legally produce custom medications for individual patients. The endorsement heightens the chance that the FDA could formally change its stance on these ingredients, even as questions linger about their safety and effectiveness. The panel's narrow majority vote represents a victory for Health and Human Services Secretary Robert F. Kennedy Jr. and his "MAHA" agenda, which advocates for broader access to peptides.
The two-day meeting that began on Thursday brought together career FDA scientists, medical experts, and supporters of expanded peptide use. The outcome reflects an unusual and high-profile collision between these groups. The FDA usually, but not always, sides with its advisory committees, making this recommendation significant.
The four peptides under consideration were KPV and TB-500, evaluated for wound healing, BP-157 for ulcerative colitis, and MOTs-C for weight loss. The FDA had banned these peptides three years ago due to safety concerns and a lack of rigorous testing for their purported uses. Since then, they have soared in popularity among wellness influencers, been personally embraced by Kennedy, and are sold on the grey market.
The advisory panel is scheduled to debate opening up use of three other peptides on Friday: Emideltide, Semax, and Epitalon. These deliberations continue the broader push to reclassify peptides, which would allow compounding pharmacies to produce higher quality versions than the "research grade" products many Americans currently purchase from questionable sources. Kennedy has told podcaster Joe Rogan that he is a "big fan" of peptides and has used them personally. He argues that reclassifying them would give patients access to better-regulated options for weight loss, muscle gain, or shinier skin.
Despite the endorsements, the peptides in question lack substantive proof of efficacy and safety. In briefing documents filed ahead of the meeting and during presentations on Thursday, FDA reviewers advised against broader use. They cited the absence of available evidence and the resulting unknowns about true risks and benefits. Some reports have documented dangerous side effects associated with these peptides.
The agency's reviewers emphasized that safety concerns led to the initial ban three years ago. The peptides have not been rigorously tested for their purported uses. Supporters of broader use, however, point to either a lack of clearly established safety issues or the opportunity to offer patients a more regulated choice than what is currently available on the grey market.
The advisory panel included several members with conflicts of interest, such as a history of prescribing or selling peptides. This unusual composition, combined with the FDA's initial move in April to schedule the meeting, has intensified concerns that politics and ideology are influencing the agency's decision-making. The meeting's outcome is not likely to calm those fears. Each vote on Thursday was close, with a divided panel narrowly recommending broader use. The clashes involved weighing the risks of broader use against keeping the status quo in place.
Supporters of broader use, many of whom had ties to businesses that sell peptides, argued that the current situation poses its own risks. Panelist Haleem Mohammed, a physician and Chief Medical Officer of Gameday Men's Health, a network of clinics that offers peptides, stated, "There's stuff happening out there that we need to try and control and make sure that we keep patients as safe as possible."
Dissenters expressed concern that positive votes could create larger problems. Elizabeth Rebello, the executive director of Anesthesiology, Critical Care and Pain Medicine at University of Texas MD Anderson Cancer Center, said, "I'm concerned that we're responding to a market-induced demand rather than a decision based in solid science." Brian Lee, an associate professor of medicine at USC's Keck School of Medicine, voiced worries about patient safety and the precedent being set by the proceedings. Regarding the peptide BP-157, Lee said, "I think this endorsement can be potentially harmful, and I cannot, in good conscience, vote yes." Lee also called on the FDA to "standardize" decision-making on these products going forward, arguing that such decisions "should be objective and based on facts, not subjective and based on opinion."
Peptides referenced: TB-500, MOTS-c, Epithalon, Semax.
Related reading: FDA Panel Backs Loosening Restrictions on Four Peptides Amid Safety Doubts, FDA Peptide Shift and Leadership Change Could Affect Hims and Hers Health, FDA Advisers Endorse First of Seven Peptides for Regulatory Flexibility, FDA Panel Reviews Peptides, Considers Loosening Rules for Unapproved Therapies.